243 related articles for article (PubMed ID: 20075644)
1. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.
Shram MJ; Sathyan G; Khanna S; Tudor IC; Nath R; Thipphawong J; Sellers EM
J Clin Psychopharmacol; 2010 Feb; 30(1):25-33. PubMed ID: 20075644
[TBL] [Abstract][Full Text] [Related]
2. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
4. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
[TBL] [Abstract][Full Text] [Related]
5. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.
Devarakonda K; Kostenbader K; Zheng Y; Montgomery JB; Barrett T; Young JL; Webster LR
Postgrad Med; 2015 Jan; 127(1):13-21. PubMed ID: 25584931
[TBL] [Abstract][Full Text] [Related]
6. Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivity.
Cruciani RA; Katz N; Portenoy RK
J Pain; 2012 Apr; 13(4):379-89. PubMed ID: 22424912
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.
Vashi V; Harris S; El-Tahtawy A; Wu D; Cipriano A
J Clin Pharmacol; 2005 May; 45(5):547-54. PubMed ID: 15831778
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
[TBL] [Abstract][Full Text] [Related]
10. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
11. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.
Morton T; Kostenbader K; Montgomery J; Devarakonda K; Barrett T; Webster L
Postgrad Med; 2014 Jul; 126(4):20-32. PubMed ID: 25141240
[TBL] [Abstract][Full Text] [Related]
12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
13. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
14. Alprazolam absorption kinetics affects abuse liability.
Mumford GK; Evans SM; Fleishaker JC; Griffiths RR
Clin Pharmacol Ther; 1995 Mar; 57(3):356-65. PubMed ID: 7697954
[TBL] [Abstract][Full Text] [Related]
15. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
[TBL] [Abstract][Full Text] [Related]
16. The abuse potential of Remoxy(®), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.
Setnik B; Roland CL; Cleveland JM; Webster L
Pain Med; 2011 Apr; 12(4):618-31. PubMed ID: 21463474
[TBL] [Abstract][Full Text] [Related]
17. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
Hagen NA; Babul N
Cancer; 1997 Apr; 79(7):1428-37. PubMed ID: 9083166
[TBL] [Abstract][Full Text] [Related]
18. Dose proportionality of the pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR).
Durnin C; Hind ID; Ghani SP; Yates DB; Cross M
Proc West Pharmacol Soc; 2001; 44():73-4. PubMed ID: 11794000
[No Abstract] [Full Text] [Related]
19. Oral hydromorphone extended-release.
Guay DR
Consult Pharm; 2010 Dec; 25(12):816-28. PubMed ID: 21172762
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of morning vs. evening dosing of extended-release hydromorphone on sleep physiology in patients with low back pain: a pilot study.
Webster LR; Smith MD; Mackin S; Iverson M
Pain Med; 2015 Mar; 16(3):460-71. PubMed ID: 25279807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
